RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RVL Pharmaceuticals Stock

RVL Pharmaceuticals Stocks 2025

RVL Pharmaceuticals Stocks

89.8 M

Ticker

RVLPQ

ISIN

IE00BF2HDL56

WKN

A2N6WE

In 2025, RVL Pharmaceuticals had 89.8 M outstanding stocks, a 0% change from the 89.8 M stocks in the previous year.

The RVL Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2028e89.8
2027e89.8
2026e89.8
2025e89.8
2024e89.8
2023e89.8
202289.8
202167.4
202060.7
201952.4
201845.3
201742.9
201651.2

RVL Pharmaceuticals shares outstanding

The number of shares was RVL Pharmaceuticals in 2024 — This indicates how many shares 89.8 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RVL Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RVL Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RVL Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RVL Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RVL Pharmaceuticals Aktienanalyse

What does RVL Pharmaceuticals do?

Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating RVL Pharmaceuticals's Shares Outstanding

RVL Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in RVL Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding RVL Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in RVL Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about RVL Pharmaceuticals stock

How many stocks are there of RVL Pharmaceuticals?

The current number of stocks of RVL Pharmaceuticals is 89.8 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of RVL Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of RVL Pharmaceuticals evolved in recent years?

The number of shares of RVL Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. RVL Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of RVL Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does RVL Pharmaceuticals pay?

Over the past 12 months, RVL Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RVL Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of RVL Pharmaceuticals?

The current dividend yield of RVL Pharmaceuticals is .

When does RVL Pharmaceuticals pay dividends?

RVL Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RVL Pharmaceuticals?

RVL Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of RVL Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RVL Pharmaceuticals located?

RVL Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von RVL Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RVL Pharmaceuticals from 2/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/1/2025.

When did RVL Pharmaceuticals pay the last dividend?

The last dividend was paid out on 2/1/2025.

What was the dividend of RVL Pharmaceuticals in the year 2024?

In the year 2024, RVL Pharmaceuticals distributed 0 USD as dividends.

In which currency does RVL Pharmaceuticals pay out the dividend?

The dividends of RVL Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RVL Pharmaceuticals

Our stock analysis for RVL Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RVL Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.